文献速递心脑血管急症消化、代谢与肾脏急症

阿司匹林在糖尿病患者一级预防中的作用

Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
PubMed 文献 · N Engl J Med · 2018-08-26
一句话结论无明确心血管疾病的糖尿病患者每日服用阿司匹林100 mg可减少严重血管事件,但大出血风险增加,绝对获益与出血风险基本相抵。

ASCEND试验将15,480例无明确心血管疾病的成人糖尿病患者随机分配至阿司匹林100 mg每日一次组或匹配安慰剂组。平均随访7.4年,阿司匹林组严重血管事件发生率显著低于安慰剂组(8.5% vs 9.6%,率比0.88,95%CI 0.79-0.97,P=0.01),但大出血事件显著增加(4.1% vs 3.2%,率比1.29,95%CI 1.09-1.52,P=0.003),主要为胃肠道出血和其他颅外出血。胃肠道肿瘤及所有肿瘤发生率两组无显著差异。结论认为阿司匹林预防了严重血管事件但也导致大出血,绝对获益与出血风险基本相抵。

要点

  • 无明确心血管疾病的糖尿病患者,阿司匹林100 mg每日一次使严重血管事件从9.6%降至8.5%(率比0.88,95%CI 0.79-0.97,P=0.01)。
  • 同一人群阿司匹林100 mg每日一次使大出血事件从3.2%升至4.1%(率比1.29,95%CI 1.09-1.52,P=0.003),主要为胃肠道出血和其他颅外出血。
  • 胃肠道肿瘤发生率阿司匹林组2.0% vs 安慰剂组2.0%,所有肿瘤11.6% vs 11.5%,两组无显著差异,长期随访仍在计划中。
  • 平均随访7.4年,阿司匹林对严重血管事件的绝对获益与出血风险基本相抵。

适用人群与场景

  • 患有糖尿病但无明确心血管疾病的成人,随机分组时纳入。

处置流程与药物剂量

  • 阿司匹林100 mg每日一次口服,与匹配安慰剂对照,用于无明确心血管疾病的成人糖尿病患者一级预防研究方案。

研究设计与关键结果

  • 研究类型为随机对照试验,共15,480例参与者随机分组。
  • 平均随访7.4年,严重血管事件(心肌梗死、卒中或短暂性脑缺血发作、或任何血管原因死亡,排除确诊颅内出血)阿司匹林组658例(8.5%)vs 安慰剂组743例(9.6%),率比0.88(95%CI 0.79-0.97),P=0.01。
  • 大出血事件(颅内出血、威胁视力的眼部出血、胃肠道出血或其他严重出血)阿司匹林组314例(4.1%)vs 安慰剂组245例(3.2%),率比1.29(95%CI 1.09-1.52),P=0.003,超额出血主要为胃肠道出血和其他颅外出血。
  • 胃肠道肿瘤阿司匹林组157例(2.0%)vs 安慰剂组158例(2.0%),所有肿瘤897例(11.6%)vs 887例(11.5%),两组无显著差异,这些结局的长期随访仍在计划中。

证据类型、等级与局限

  • 随机对照试验(ASCEND),由英国心脏基金会等资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于无明确心血管疾病的成人糖尿病患者,作者结论认为阿司匹林预防了严重血管事件但也导致大出血,绝对获益与出血风险基本相抵。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.

METHODS: We randomly assigned adults who had diabetes but no evident cardiovascular disease to receive aspirin at a dose of 100 mg daily or matching placebo. The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage). The primary safety outcome was the first major bleeding event (i.e., intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding). Secondary outcomes included gastrointestinal tract cancer.

RESULTS: A total of 15,480 participants underwent randomization. During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval [CI], 0.79 to 0.97; P=0.01). In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding. There was no significant difference between the aspirin group and the placebo group in the incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these outcomes is planned.

CONCLUSIONS: Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard. (Funded by the British Heart Foundation and others; ASCEND Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Bowman L, Mafham M, Wallendszus K, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018. PMID: 30146931. doi:10.1056/NEJMoa1804988

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。